Infinium Pharmachem Ltd. (INFINIUM-SM): Infinium Pharmachem Share Price Rises 8.37% Today as Micro Cap Stock Enters Top Gainers

Infinium Pharmachem Share Price Today rose to Rs 233, up 8.37%, taking the micro cap chemicals company’s market capitalisation to Rs 339.79 crore.

Infinium Pharmachem Share Price rose to Rs 233 on 12 August 2026, marking an 8.37% same-day gain from the previous close of Rs 215 and lifting the company’s market capitalisation to Rs 339.79 crore. For Stock Market Today participants scanning Top Gainers Today, that makes this micro cap chemicals name a verified price rise event under the workflow’s market-cap-based screen.

The supplied data confirms what happened in today’s session: Infinium Pharmachem Ltd. traded between Rs 223.5 and Rs 234.45 after opening at Rs 224.5, with total volume of 4,000 shares on NSE and turnover of Rs 0.09 crore. The move is relevant because it pushed the stock well above its previous close and near the day’s high early in the session, placing Infinium Pharmachem Share Price Today firmly in Stocks in News and Market Movers conversations.

What is not established by the supplied data is a company-specific catalyst. So, in this Infinium Pharmachem Stock News update, Univest focuses on the verified market evidence: price action, valuation, profitability, sector context and peer positioning. The numbers show a stock that is small in market cap, profitable on return metrics and trading at a P/E of 27.58 and P/B of 3.06 within the Chemicals industry. Investors tracking Infinium Pharmachem Share Price, Infinium Pharmachem Share Price Live trends and Infinium Pharmachem Latest News should monitor whether this move is sustained by continued trading participation, relative valuation support and ongoing financial quality.

Infinium Pharmachem Ltd. (INFINIUM-SM) Share Price Today: Price Action Analysis

Infinium Pharmachem Ltd. (INFINIUM-SM) traded at Rs 233. versus the previous close of Rs 215, a rise of 8.37%. The stock opened at Rs 224.5, reached Rs 234.45, touched Rs 223.5. Reported volume was 4,000.

Infinium Pharmachem Ltd. (INFINIUM-SM) Fundamental Analysis

Infinium Pharmachem Ltd. was valued at a P/E ratio of 27.58x, a P/B ratio of 3.06x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 48.44% and ROCE of 32.14%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 7.8, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Infinium Pharmachem Fundamental Analysis shows a micro cap company with notable return ratios and mid-range valuation multiples relative to its industry dataset. That combination helps explain why the stock is attracting investor attention today, even though the supplied data does not identify a specific news catalyst.

At the current price of Rs 233, Infinium Pharmachem Share Price values the company at a market capitalisation of Rs 339.79 crore. That places it above the industry median market cap of Rs 235.09 crore but below the industry average of Rs 572.1 crore within the supplied Chemicals benchmark universe. In size terms, it is still clearly a small listed company, which often means price moves can look sharper because the base is smaller. Market capitalisation, however, indicates company size, not business quality.

On valuation, the stock trades at a P/E ratio of 27.58 and a P/B ratio of 3.06. Those numbers matter because they frame how investors are valuing current earnings and net worth. A P/E of 27.58 means the market is pricing the stock at 27.58 times earnings, while a P/B of 3.06 means it trades at 3.06 times book value. Infinium Pharmachem Share Price therefore carries a valuation premium to the industry median P/E of 21.25 and median P/B of 1.6, though it remains below the industry average P/E of 47.76. That makes the stock neither a clear outlier on the high side nor a deep value case based on the supplied peer set.

Profitability metrics are stronger. Return on equity stands at 48.44%, while return on capital employed is 32.14%. Both figures are materially above the industry medians of 11.96% for ROE and 14.37% for ROCE, and also above the industry averages of 15.5% and 17.65% respectively. In plain terms, the company’s reported profitability ratios are substantially ahead of a large part of the Chemicals benchmark. For investors reading Infinium Pharmachem Financial Results trends through ratio data, that is a major point of interest.

EPS is Rs 7.8, which indicates the earnings attributable to each share based on the supplied data. With Infinium Pharmachem Share Price at Rs 233, that EPS feeds directly into the 27.58 P/E multiple. Dividend yield is 0, signalling that the current or historical payout reflected in the dataset is nil relative to the current market price. This does not change the earnings picture, but it does show that the stock’s present appeal, if any, is tied more to market performance and profitability metrics than to income yield. On balance, the supplied fundamentals add context to today’s move by showing a profitable micro cap trading above median sector valuation levels, which naturally leads to a closer look at industry positioning.

Sector and Industry Context

Infinium Pharmachem Ltd. (INFINIUM-SM) is classified under sector: Chemicals and industry: Chemicals.

Infinium Pharmachem Ltd. (INFINIUM-SM) has a P/E ratio of 27.58x, which is above the benchmark median of 21.25x, a difference of +29.79%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Infinium Pharmachem Ltd. (INFINIUM-SM) has a ROE of 48.44%, which is above the benchmark median of 11.96%, a difference of +305.02%. Infinium Pharmachem Ltd. (INFINIUM-SM) has a ROCE of 32.14%, which is above the benchmark median of 14.37%, a difference of +123.66%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

The Chemicals industry data gives important perspective on whether today’s move in Infinium Pharmachem Share Price looks isolated or broadly aligned with sector valuation patterns. Based on the supplied benchmark, the stock sits in a large peer universe where profitability stands out more clearly than raw size.

The sectorSnapshot is built on the same industry and covers 141 companies, giving this article a broad benchmark scope for Chemicals. Within that universe, Infinium Pharmachem Share Price carries a company P/E of 27.58. That is above the benchmark median P/E of 21.25, but below the benchmark average P/E of 47.76. The range is wide, from 1.39 to 798.3 across 115 companies with reported P/E data, which suggests valuation dispersion is significant in this industry. Relative to that spread, Infinium Pharmachem is trading above the middle of the pack, but not at the most extreme end.

The company’s P/B ratio of 3.06 is also above the benchmark median of 1.6 and average of 1.77 across 140 companies. That suggests investors are placing a higher multiple on net worth than they do for a typical Chemicals stock in this sample. Whether that is justified usually depends on profitability, and here the return ratios become important. Infinium Pharmachem reports ROE of 48.44% versus the industry median of 11.96% and average of 15.5%. Its ROCE of 32.14% also exceeds the median of 14.37% and average of 17.65%.

In other words, Infinium Pharmachem Share Price is not cheap relative to median industry valuation metrics, but its profitability profile is also much stronger than median and average benchmark figures. On size, the company’s market capitalisation of Rs 339.79 crore is above the industry median of Rs 235.09 crore and below the average of Rs 572.1 crore, with the industry ranging from Rs 5.23 crore to Rs 3,136.86 crore. For Univest readers following Infinium Pharmachem Share Price News and broader NSE News or BSE News flows, the key sector takeaway is straightforward: this stock is being valued at a premium to typical industry medians, but the premium is paired with above-benchmark return metrics.

Peer Comparison

Infinium Pharmachem Ltd. (INFINIUM-SM) has a P/E ratio of 27.58x compared with the displayed peer median of 18.58x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 48.44% compares with a peer median of 14.35% across the companies shown in the table. ROCE stood at 32.14% versus the displayed peer median of 24.37%, providing a capital-efficiency comparison. Infinium Pharmachem Ltd. (INFINIUM-SM) has a market capitalisation of Rs 339.79 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Peer comparison shows that Infinium Pharmachem Share Price sits far below the larger listed chemicals names on market capitalisation, but its return metrics compare more favourably than several peers. That contrast is one reason the stock can attract interest when it appears in top-gainer lists.

Against Bhansali Engineering Polymers Ltd., Infinium Pharmachem is much smaller at Rs 339.79 crore versus Rs 3,136.86 crore. Yet its ROE of 48.44% is above Bhansali’s 42.11%, while its ROCE of 32.14% trails Bhansali’s much stronger 56.88%. Bhansali’s P/E of 15.24 and P/B of 2.65 are lower than Infinium’s 27.58 and 3.06, suggesting the larger company trades on cheaper earnings and book multiples.

Compared with Grauer & Weil (India) Ltd., which has a market cap of Rs 3,067.33 crore, Infinium Pharmachem Share Price again looks smaller but stronger on profitability. Grauer & Weil reports ROE of 14.35% and ROCE of 19.47%, both well below Infinium’s 48.44% and 32.14%. Its P/E of 19.11 and P/B of 2.73 are also lower than Infinium’s figures.

Rossari Biotech Ltd. trades at a P/E of 18.58, P/B of 2.06, ROE of 16.17% and ROCE of 24.37% with a market cap of Rs 2,824.55 crore. Here too, Infinium Pharmachem shows higher profitability ratios but commands richer earnings and book multiples. Nocil Ltd., by contrast, has a higher P/E of 41.89 but lower P/B of 1.55, ROE of 12.95% and ROCE of 17.71% at a market cap of Rs 2,788.48 crore. JG Chemicals Ltd. offers another useful reference point with P/E of 32.36, P/B of 4.39, ROE of 29.78% and ROCE of 29.05%; Infinium is cheaper on both P/E and P/B than JG Chemicals while posting higher ROE and slightly higher ROCE.

Among the supplied peers, Jubilant Agri N Con Pro L is the closest on profitability, with ROE of 48.1% and ROCE of 34.45%, versus Infinium’s 48.44% and 32.14%. Its P/E of 21.65 is lower, while its P/B of 6.11 is much higher. For Univest’s Infinium Pharmachem Stock Analysis, that peer mix suggests the stock is not the cheapest in the Chemicals basket, but it is competitive on return metrics despite its significantly smaller market size.

Why Investors Are Watching Infinium Pharmachem

Infinium Pharmachem Share Price has moved onto investor radars because today’s gain is large enough to stand out in a micro cap setting, while the supporting ratio profile is stronger than many companies in the same Chemicals universe. In Market News and Stock Updates terms, the interest is not just about a one-day price rise; it is also about how the stock’s valuation and profitability compare with the wider listed industry.

• Verified price action: the stock rose Rs 18, or 8.37%, from Rs 215 to Rs 233, after opening at Rs 224.5 and trading between Rs 223.5 and Rs 234.45.
• Trading participation: total NSE volume stood at 4,000 shares, with turnover of Rs 0.09 crore.
• Fundamental context: the company trades at P/E of 27.58 and P/B of 3.06, with ROE of 48.44%, ROCE of 32.14% and EPS of Rs 7.8.
• Sector positioning: its P/E is above the Chemicals median of 21.25, but below the average of 47.76.
• Profitability edge: its ROE and ROCE are both above industry medians and averages in the supplied 141-company benchmark.

What investors should monitor next is whether Infinium Pharmachem Share Price continues to hold above the prior close while market participation remains steady. They should also watch how the stock’s premium-to-median valuation is assessed against its stronger profitability profile. For readers following Stocks Rising Today on Univest, that balance between price momentum and ratio support is the central issue.

About Infinium Pharmachem

Infinium Pharmachem Ltd. is listed under the Chemicals sector and Chemicals industry, placing it within a broad universe of 141 same-industry companies in the supplied benchmark. While the dataset does not provide a long business description, the stock’s classification gives enough context to place it within the listed Indian chemicals space tracked across NSE and BSE.

For investors trying to understand Infinium Pharmachem Share Price beyond a one-day move, the most useful verified context is that the company operates in an industry with widely varying valuation and profitability profiles. The Chemicals basket in the benchmark includes much larger names such as Bhansali Engineering Polymers, Grauer & Weil, Chemplast Sanmar, Rossari Biotech and Nocil, all with market capitalisations far above Infinium’s Rs 339.79 crore. That means Infinium is a relatively small participant in its industry by listed-market standards, even though it sits above the benchmark median market cap.

Its current market position in this article is therefore best understood through numbers rather than narrative claims: a micro cap chemicals company, a market value of Rs 339.79 crore, a P/E of 27.58, a P/B of 3.06, ROE of 48.44%, ROCE of 32.14% and a dividend yield of 0. For Univest readers seeking Infinium Pharmachem Company News, that makes the company worth tracking not because of unsupported headlines, but because its listed-market profile combines small size with unusually strong reported return ratios versus sector benchmarks.

Track Infinium Pharmachem Share Price on Univest

Use Infinium Pharmachem Ltd. (INFINIUM-SM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Infinium Pharmachem Share Price more closely can use Univest to track live share price movements, day change, market capitalisation, 52-week levels, technical indicators when available, valuation ratios and shareholding pattern updates as they are reported. Univest also helps users compare stocks across sector benchmarks and peer groups, which is particularly useful when a micro cap name appears among Top Gainers Today.

For readers monitoring Infinium Pharmachem Share Price Today, Infinium Pharmachem Share Price Live moves, or Infinium Pharmachem Latest News, the value lies in watching how current price action interacts with profitability metrics like ROE and ROCE, and with valuation measures such as P/E and P/B. Univest makes that cross-check easier in one place without turning a market update into a recommendation.

Frequently Asked Questions

What is Infinium Pharmachem Share Price Today?

Ans. Infinium Pharmachem Share Price Today is Rs 233. The stock rose Rs 18 from the previous close of Rs 215, translating into an 8.37% gain during the session covered in this market update.

Why is Infinium Pharmachem share price rising today?

Ans. The supplied data confirms that Infinium Pharmachem shares rose 8.37% today and entered a qualifying price-rise screen for a micro cap stock. It shows the move happened, but it does not establish a company-specific catalyst.

What were the day high, day low and opening price?

Ans. Infinium Pharmachem opened at Rs 224.5, touched a day high of Rs 234.45 and a day low of Rs 223.5. Those figures show the stock stayed above the previous close of Rs 215 throughout the supplied session.

What is the market capitalisation of Infinium Pharmachem Ltd.?

Ans. Infinium Pharmachem Ltd. has a market capitalisation of Rs 339.79 crore based on the supplied data. That places it in the Micro Cap category and above the Chemicals industry median market cap of Rs 235.09 crore.

How much volume was traded in Infinium Pharmachem today?

Ans. Total traded volume in Infinium Pharmachem stood at 4,000 shares, with all 4,000 shares reported on NSE. The turnover for the session was Rs 0.09 crore, indicating modest absolute trading activity.

Is Infinium Pharmachem expensive compared with its Chemicals industry benchmark?

Ans. Infinium Pharmachem trades at a P/E of 27.58 versus the industry median of 21.25 and average of 47.76. Its P/B of 3.06 is also above the benchmark median of 1.6 and average of 1.77.

How strong are Infinium Pharmachem’s profitability ratios?

Ans. The company’s ROE is 48.44% and ROCE is 32.14%. Both are well above the Chemicals industry medians of 11.96% and 14.37%, and also above the benchmark averages of 15.5% and 17.65%.

What is the EPS of Infinium Pharmachem?

Ans. Infinium Pharmachem reports EPS of Rs 7.8 in the supplied dataset. EPS represents earnings attributable to each share and is one of the inputs that supports the stock’s current P/E ratio of 27.58.

Does Infinium Pharmachem pay a dividend?

Ans. The supplied data shows a dividend yield of 0 for Infinium Pharmachem. That means the current dataset does not reflect a dividend return relative to the prevailing market price of Rs 233.

How does Infinium Pharmachem compare with selected listed peers?

Ans. Infinium Pharmachem is far smaller than peers like Bhansali Engineering Polymers, Rossari Biotech and Nocil on market cap, but its ROE of 48.44% and ROCE of 32.14% compare favourably with several supplied companies.